Overall The mission of the UAB CFAR is to support the conduct of cutting-edge research in basic science, therapeutics, prevention, community engaged research, and clinical manifestations and pathogenesis of HIV and related disorders. Five core facilities provide vital support for the Center's principal thematic areas of its scientific agenda. To optimize our CFAR operation, an intensive strategic planning process has established efficiencies through streamlining its cores from 7 to 5, taking full advantage of existing services provided by other centers on campus, outsourcing under-utilized services, and allowing for investments in new areas (Specific Aims workshops, Transplant Tissue Procurement Facility, and Ending HIV in Alabama SWG). The Center includes 185 members from over 30 divisions and departments within UAB. Over the last 4 years, the UAB CFAR has enabled research leading to FRB / total funding of $21M / $66M. The majority (62%) was newly obtained in this budget period; 57% of these are related to basic science, 18% to population health prevention and treatment research, 22% to behavioral epi and intervention research, and 3% to community engaged research. Since our last renewal, the center has increased the number of young investigators supported by training awards from 7 to 16 (14 women; 5 under-represented minorities, URMs) and invested $1.9M in new-investigator pilot awards yielding $25M in outside funding. Overall, for our ROI in pilot funding is 13:1 in new extramural grants awarded. The Center helped recruit 45 new HIV/AIDS investigators in the last 4 years (17 external, 28 new to HIV research), of whom 21 are women and 5 URMs. Across all cores the CFAR supported 61 unique, NIH-funded projects (FRB) and 404 other NIH-funded projects, of which 309 were HIV-specific resulting in over 1000 HIV publications, and in the garnering of strong Institutional support. Over the next 5 years we will: (1) Continue to enhance the productivity of ongoing research programs by enabling interdisciplinary research through the provision of critical shared resource facilities and administrative and fiscal management support to Center investigators (2) Use robust strategic planning methods to identify new research opportunities and priorities that align with existing CFAR programs and foster new research programs where none are in existence, but where faculty interest is evident; (3) Stimulate the entry of early stage and established faculty into HIV/AIDS research programs through mentoring programs for young investigators and through a robust, peer-reviewed Developmental Grants Program; (4) Provide a central focus for HIV/AIDS research activities at UAB that emphasize effective communication and collaboration among CFAR members with the wider HIV/AIDS research community; and (5) Promote faculty recruitment and program development in areas that reflect the ongoing evolution of HIV/AIDS research in Alabama, the United States, and around the world. The UAB CFAR will foster HIV/AIDS research that has high local, national, and international impact and in so doing will promote the NIH priorities of innovation and effectiveness in AIDS treatment and prevention.

Public Health Relevance

Overall The UAB Center for AIDS Research provides scientific direction, strategic planning, and implementation of services to advance the field of HIV research. The Center powers studies to understand the basic biology of HIV, therapeutic efficacy, and prevention, specifically vaccine development and community based interventions that reduce new transmissions throughout Alabama, the Southeastern United States, and the world.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027767-31
Application #
9761778
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
1997-03-01
Project End
2024-05-31
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
31
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Ladowski, Joseph M; Reyes, Luz M; Martens, Gregory R et al. (2018) Swine Leukocyte Antigen Class II Is a Xenoantigen. Transplantation 102:249-254
Owens, Michael A; Parker, Romy; Rainey, Rachael L et al. (2018) Enhanced facilitation and diminished inhibition characterizes the pronociceptive endogenous pain modulatory balance of persons living with HIV and chronic pain. J Neurovirol :
Chakraborty, Asmi; Dorsett, Kaitlyn A; Trummell, Hoa Q et al. (2018) ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem 293:984-994
Stringer, Kristi Lynn; Azuero, Andres; Ott, Corilyn et al. (2018) Feasibility and Acceptability of Real-Time Antiretroviral Adherence Monitoring among Depressed Women Living with HIV in the Deep South of the US. AIDS Behav :
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Stafman, Laura L; Mruthyunjayappa, Smitha; Waters, Alicia M et al. (2018) Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget 9:22665-22679
Yang, Zhenhua; Shah, Kushani; Busby, Theodore et al. (2018) Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest 128:3605-3618
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428

Showing the most recent 10 out of 955 publications